An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

European Respiratory Journal

Volumn 10, Issue 4, 1997, Pages 815-821

  Boyd, G ^a   Morice, A H ^b   Pounsford, J C ^c   Siebert, M ^d   Peslis, N ^d   Crawford, C ^e  

^a STOBHILL HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c FRENCHAY HOSPITAL   (United Kingdom)

^d Glaxo Group Research Ltd ^*  (Germany)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Clinical trial; Placebo; Salmeterol; Six minute walk; Symptom score

Indexed keywords

PLACEBO; SALMETEROL XINAFOATE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOM;

ADULT; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EVALUATION STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030937798     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Thom TJ. International comparisons in COPD mortality. Am Rev Respir Dis 1989; 140: S27-S3 4.
2. Manfreda J, Mao Y, Litven W. Morbidity and mortality from chronic obstructive airways disease. Am Rev Respir Dis 1989; 140: S19-S26.
3. Feinleib M, Rosenberg HM, Collins JG, Delozier JE, Pokras R, Chevarley FM. Trends in COPD morbidity and mortality in the United States. Am Rev Respir Dis 1989; 140: S9-S18.
4. Lebowitz MD. The trends in airways obstructive disease morbidity in the Tuscon epidemiological study. Am Rev Respir Dis 1989; 140: S35-S41.
5. Fletcher CM, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648.
6. Speizer FE, Tager IB. Epidemiology of chronic mucus hypersecretion and obstructive airways disease. Epidemiol Rev 1979; 1: 124-142.
7. Britton M. Salmeterol and salbutamol: large multicentre studies. Eur Respir Rev 1991; 4: 288-292.
8. Faurschou P. Chronic dose-ranging studies with salmeterol. Eur Respir Rev 1991; 4: 282-287.
9. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic airflow limitation. Am Rev Respir Dis 1987; 135: 1069-1074.
10. Higgins BG, Powell TM, Cooper S. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4: 415-420.
11. Karpel JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991; 99: 871-876.
12. Levy SF. Bronchodilators in COPD. Chest 1991; 99: 793-794.
13. Postma DS. Inhaled therapy in COPD: what are the benefits? Respir Med 1991; 85: 447-449.
14. Palmer JBD, Stuart AM, Shepherd GL, Viskum K. Inhaled salmeterol in the treatment of patients with moderate-to-severe reversible obstructive airways disease: a three month comparison of the efficacy and safety of twice daily salmeterol (100 μg) with salmeterol (50 μg). Respir Med 1992; 86: 409-417.
15. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnoea. Chest 1988; 93(3): 580-586.
16. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381.
17. van Elteren PH. On the combination of independent two sample test of Wilcoxon. Bull Int Stat Inst 1960; 37: 351-361.
18. Siafakas NM, Vermeire P, Pride NB, et al. on behalf of task force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
19. Engel T, Heining JH, Madson O. A trial of inhaled budesonide on airways responsivesness in smokers with chronic bronchitis. Eur Respir J 1989; 2: 935-939.
20. Auffarth B, Postma DS, DeMonchy JGR. Effects of inhaled budesonide on spirometry, reversibility, airway responsiveness and cough threshold in smokers with COPD. Thorax 1991; 46: 372-377.
21. Pride NB, Taylor RG, Lins H. Bronchial hyperresponsiveness as a risk factor for progressive airflow obstruction in smokers. Bull Eur Physiopathol Respir 1987; 23: 369-375.
22. Weir DC, Gove RL, Robertson AJ. Corticosteroid trials in nonasthmatic chronic airflow obstruction. Thorax 1990; 45: 112-117.
23. O'Donnell DE. Breathlessness in patients with chronic airflow limitation, mechanisms and management. Chest 1994; 106: 904-912.
24. Wolkove N, Dejczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnoea in obstructive lung diseases. Chest 1989; 96: 1247-1251.
25. Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenal and orally-administered theophylline in patients with chronic airflow obstruction. Chest 1989; 89: 171-173.
26. Murciano D, Auclair M-H, Pariente R, Aubier M. A randomised, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-1525.
27. Webb K, Fox L, Muri C, O'Donnell DE. Ipratropium bromide reduces extertional dyspnea in patients with severe chronic airflow limitation (CAL) (Abstract). Chest 1990; 98: 113S.
28. Jones PW, Bosh TK. Improvements in quality of life in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1995; 151(4): A464.
29. Van Schyack CP, Dampeling E, Van Herisaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on-demand? A randomised controlled study. BMJ 1991; 303: 1426-1430.
30. Van Schyack CP, Dompeling E, Van Herwaarden GL, et al. Continuous use of bronchodilators versus use ondemand in mild asthma and COPD (Abstract). Am J Respir Crit Care Med 1994; 149: A203.
31. Pearlman DS, Chervinsky P, La Force C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327(1): 420-425.
32. Boyd G, on behalf of a UK Study Group. Salmeterol xinafoate in asthmatics under consideration for maintenance oral corticosteroid therapy. Eur Respir J 1995; 8: 1494-1498.
33. Britton MG, Earnshaw JS, Palmer JBD. A 12 month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; S: 1062-1067.
34. Lundback B, Rawlinson DW, Palmer JBD. A 12 month comparison of salmeterol with salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148-153.